Metabolic HealthTirzepatide Leads on Weight Loss While Oral Orforglipron Offers a Different Trade-Off
A study combined clinical trial evidence with computer models to compare oral orforglipron with injectable semaglutide and tirzepatide. In the direct SURMOUNT-5 trial, tirzepatide produced average weight loss of 20.2%, compared with 13.7% for semaglutide, at 72 weeks. Tirzepatide also ranked highest in models emphasizing effectiveness, safety, or balanced priorities, although these rankings do not prove superior safety. Orforglipron led when the model prioritized accessibility, reflecting its oral formulation and potential for manufacturing at scale rather than proven affordability. Most rankings held up when assumptions changed, but the balanced model was less stable. The takeaway is that no drug wins on every consideration: treatment should reflect individual goals and preferences. This abstract-based summary cannot establish which option is best for a particular patient or whether any extends lifespan.
